Approved and investigational therapies include PPARγ agonists (pioglitazone) for diabetes, FXR agonists (OCA) for liver disease, LXR modulators for atherosclerosis, and THR-β agonists (resmetirom) for MASH. Here, THRB is linked to liver disorder.